

**OPTN Minority Affairs Committee
Meeting Summary
February 28, 2022
Conference Call**

**Paulo Martins, MD, PhD, Chair
Alejandro Diez, MD, Vice Chair**

Introduction

The OPTN Minority Affairs Committee (the Committee) met via Citrix GoToMeeting teleconference on 02/28/2022 to discuss the following agenda items:

1. *Continuous Distribution of Kidneys & Pancreata Request for Feedback*, OPTN Kidney & Pancreas Transplantation Committees
2. *Change Calculated Panel Reactive Antibody (CPRA) Calculation*, OPTN Histocompatibility Committee
3. Winter 2022 Public Comment Update: *Establish OPTN Requirement for Race- Neutral eGFR Calculations*

The following is a summary of the Committee's discussions.

1. *Continuous Distribution of Kidneys & Pancreata Request for Feedback*, OPTN Kidney & Pancreas Transplantation Committees

The Committee heard and provided feedback on the *Continuous Distribution of Kidneys & Pancreata Request for Feedback*.

Summary of discussion:

A member confirmed that following this request for feedback, the OPTN Kidney & Pancreas Transplantation Committees will release a proposal to the winter 2023 public comment period and be received for action by the OPTN Board of Directors (BOD) in June 2023. Another member asked if the Continuous Distribution of Kidneys & Pancreata would have any impact on pediatric kidney allocation. The presenter responded that pediatrics has been placed in the patient access identified attribute, which means that the sponsoring committees seek to give the pediatric population increasing access.

Next steps:

The Committee will draft an official comment to be posted to the OPTN website.

2. *Change Calculated Panel Reactive Antibody (CPRA) Calculation*, OPTN Histocompatibility Committee

The Committee heard and provided feedback on the *Change Calculated Panel Reactive Antibody (CPRA) Calculation* public comment proposal.

Summary of discussion:

A member asked about any disadvantage to CPRA being viewable for all candidates. The presenter responded that this change would actually provide more data and information when a program assigns unacceptable antigens for a non- renal candidate. Another member asked about the amount of

resources that would be necessary to make CPRA viewable for all candidates. Members agreed that one week for kidney programs to obtain documentation for allocation priority for CPRA 99-100% candidates felt like too short of a transition time. The presenter noted that the Histocompatibility committee has received similar feedback about the proposal. If implemented, some candidates who previously had a longer time to transplant could be transplanted rapidly and may need more than one week's time to be seen by their transplant program to ensure they are ready for transplant.

Next steps:

The Committee will draft an official comment to be posted to the OPTN website.

3. Winter 2022 Public Comment Update: *Establish OPTN Requirement for Race- Neutral eGFR Calculations*

The Committee reviewed feedback to- date on *the Establish OPTN Requirement for Race- Neutral eGFR Calculations* public comment proposal.

Summary of discussion:

A member asked if any rationale was provided with the one opposing sentiment poll result received from Region 5. Staff responded that no narrative response was submitted with this sentiment.

Next steps:

The Committee will continue to monitor feedback on *Establish OPTN Requirement for Race- Neutral eGFR Calculations* through the end of public comment.

Upcoming Meeting

- March 21, 2022 @ 1PM ET

Attendance

- **Committee Members**
 - Amaka Eneanya
 - Ayana Andrews- Joseph
 - Christine Hwang
 - Jason Narverud
 - Juan del Rio Martin
 - Manuel Rodriguez
 - Okechukwu Ojogho
 - Oscar Serrano
 - Paulo Martins
 - Stephen Gray
 - Tahaunty Pena
 - Wayne Tsuang
- **HRSA Representatives**
 - Jim Bowman
- **SRTR Staff**
 - Christian Folken
 - Monica Colvin
 - Warren McKinney
- **UNOS Staff**
 - James Alcorn
 - Jesse Howell
 - Susan Tlusty
 - Kelley Poff
 - Lindsay Larkin